ALPHARETTA, Ga. , Oct. 23, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) will webcast its conference call discussing financial results and business highlights for the third quarter 2024 on Wednesday, Oct. 30 at 9 a.m., ET. The company will issue a news release detailing its results before the market opens that same day.

The conference call will be hosted by Joe Woody, chief executive officer, and Michael Greiner, senior vice president, chief financial officer, and chief transformation officer.

To join the live conference call, dial 1-800-836-8184 in the United States. A simultaneous webcast of the call and a related presentation will be accessible via the Investors section of the Avanos Medical website, https://avanos.investorroom.com/.

A replay of the conference call will be available Oct. 30 at noon ET by dialing 1-888-660-6345 in the United States and entering passcode 38787#. It will be available for one week. A replay of the webcast also will be accessible in the Investors section of the website, approximately one hour following the completion of the conference call.

About Avanos Medical
Avanos Medical (NYSE: AVNS) is a medical technology company focused on delivering clinically superior medical device solutions that will help patients get back to the things that matter. Headquartered in Alpharetta, Georgia, Avanos is committed to addressing some of today's most important healthcare needs, including providing a vital lifeline for nutrition to patients from hospital to home, and reducing the use of opioids while helping patients move from surgery to recovery. Avanos develops, manufactures, and markets its recognized brands globally and holds leading market positions in multiple product categories. For more information, visit www.avanos.com and follow Avanos Medical on X (@AvanosMedical), LinkedIn and Facebook.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/avanos-medical-inc-to-webcast-conference-call-discussing-third-quarter-2024-financial-results-302284401.html

SOURCE Avanos Medical